Incyte Corp. (NASDAQ:INCY) said FDA accepted and granted Priority Review to an sNDA
FDA grants Priority Review to Incyte's Jakafi for acute GvHD
Products & Solutions
About Biocentury
Contact
Privacy & Legal
- Follow Us
Incyte Corp. (NASDAQ:INCY) said FDA accepted and granted Priority Review to an sNDA